Compare SFHG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFHG | CMMB |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 13.8M |
| IPO Year | 2024 | N/A |
| Metric | SFHG | CMMB |
|---|---|---|
| Price | $0.69 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | ★ 631.5K | 93.1K |
| Earning Date | 10-30-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,577,200.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.56 | N/A |
| 52 Week Low | $0.32 | $2.21 |
| 52 Week High | $2.32 | $9.84 |
| Indicator | SFHG | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 73.53 | 32.06 |
| Support Level | $0.55 | $2.44 |
| Resistance Level | $0.59 | $2.77 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 91.79 | 5.08 |
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.